Showing results (1871-1880 of 2,185) with videos related to

Sort By:
Pageof 219
Urologic Oncology|March 15, 2011
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancerYoung E Whang, Andrew J Armstrong, W Kimryn Rathmell, et al.
The Journal of Urology|November 18, 2011
Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate CenterSuzanne Biehn Stewart, Lionel L Bañez, Cary N Robertson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinomaBrian I Rini, M Dror Michaelson, Jonathan E Rosenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphomaLeigh Ellis, Yan Pan, Gordon K Smyth, et al.
Npj Health Systems|July 29, 2026
Modernizing data and data science infrastructure as a strategic asset for cancer centerYi Guo, Thomas J George, Alison M Ivey, et al.
Oncology|June 24, 2019
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid TumorsDavid Hong, Drew Rasco, Michael Veeder, et al.
BMJ Open|September 14, 2022
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trialDaniel J George, David R Spigel, Lucio N Gordan, et al.
JAMA|July 4, 2017
Effect of Radiofrequency Denervation on Pain Intensity Among Patients With Chronic Low Back Pain: The Mint Randomized Clinical TrialsJohan N S Juch, Esther T Maas, Raymond W J G Ostelo, et al.
Alimentary Pharmacology & Therapeutics|December 6, 2017
Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15)G W McCaughan, P A Thwaites, S K Roberts, et al.
Endocrinology|May 15, 2003
Developmental and hormonal signals dramatically alter the localization and abundance of insulin receptor substrate proteins in the mammary glandA V Lee, P Zhang, M Ivanova, et al.
Pageof 219